Skip to main content

NUEVOS ENFOQUES TERAPEUTICOS PARA EL CANCER DE PROSTATA HORMONO-REFRACTARIO BASADOS EN LA QUINESINA KIF11

PI17/02248

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas Jimenez, Marc
  • Masia Fandos, Nuria
  • Suarez Cabrera, Leticia
  • Olivan Riera, Mireia
  • Soriano Fernández, Aroa
  • Majem Cavaller, Blanca
  • Jimenez Jimenez, Carlos Gonzalo
  • Boloix Amenós, Ariadna
  • Toledano Martin, Ignasi
  • Navarro Jimenez, Alexandra
  • Sánchez de Toledo Codina, Josep
  • Roma Castanyer, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Santamaria Margalef, Anna
  • Guillén Burrieza, Gabriela
Inhibidor de KIF11; Terapias dirigidas; Metástasis, Inhibidor de KIF11; Teràpies dirigides; Metàstasi, KIF11 inhibitor; Targeted therapies; Metastasis, In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies., The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/01320 to Alberto Villanueva); Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099 to Marc Masanas). This work was also supported by the Asociación NEN (Nico contra el cancer infantil 2017–PVR00157).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

  • Olivan Riera, Mireia
  • Garcia Lopez, Marta
  • Suarez Cabrera, Leticia
  • Guiu, Marc
  • Gros, Laura
  • Mendez Fernández, Olga
  • Segura Ginard, Miguel
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Morote Robles, Joan
  • De la Cruz Montserrat, Fco. Xavier
  • Santamaria Margalef, Anna
Bone metastasis; MiRNAs; Prostate cancer, Metàstasi òssia; MiRNAs; Càncer de pròstata, Metástasis ósea; MiRNAs; Cáncer de próstata, About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients’ quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells’ migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b’s role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa., The study was supported by grants CPII18/00027 and PI18/01017 to A.S.; PI17/02248 to J.M.; grants PI09/00496, PI13/00173 and postdoctoral fellowship CD12/00475 of Instituto de Salud Carlos III (ISCIII), pre-doctoral fellowship of Vall d’Hebron Research Institute (VHIR), postdoctoral fellowship PERIS of Departament de Salut Govern de Catalunya to M.O.; BBVA and PID2019-104948RB-100 to M.G. (Marc Guiu) and R.R.G.; RD12/0036/0035 of Red Temática de investigación cooperativa en cancer (RTICC), and 2014SGR1330 from “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya”.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Novel KIF1A Missense Variant (R169T) Strongly Reduces Microtubule Stimulated ATPase Activity and Is Associated With NESCAV Syndrome

  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Hümmer, Stefan|||0000-0002-8184-3872
  • Masanas, Marc|||0000-0002-2249-8554
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Guitart, Maria|||0000-0003-2957-7404
  • Jeyaprakash, A. Arockia
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Ruiz, Anna|||0000-0001-7314-5962
KIF1A is a microtubule-dependent motor protein responsible for fast anterograde transport of synaptic vesicle precursors in neurons. Pathogenic variants in KIF1A have been associated with a wide spectrum of neurological disorders. Here, we report a patient presenting a severe neurodevelopmental disorder carrying a novel de novo missense variant p.Arg169Thr (R169T) in the KIF1A motor domain. The clinical features present in our patient match with those reported for NESCAV syndrome including severe developmental delay, spastic paraparesis, motor sensory neuropathy, bilateral optic nerve atrophy, progressive cerebellar atrophy, epilepsy, ataxia, and hypotonia. Here, we demonstrate that the microtubule-stimulated ATPase activity of the KIF1A is strongly reduced in the motor domain of the R169T variant. Supporting this, in silico structural modeling suggests that this variant impairs the interaction of the KIF1A motor domain with microtubules. The characterization of the molecular effect of the R169T variant on the KIF1A protein together with the presence of the typical clinical features indicates its causal pathogenic effect.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

  • Olivan, Mireia|||0000-0002-8464-0827
  • García, Marta
  • Suárez, Leticia|||0000-0002-3864-4616
  • Guiu, Marc|||0000-0002-7083-986X
  • Gros, Laura
  • Méndez Fernández, Olga
  • Rigau, Marina|||0000-0002-1691-454X
  • Reventós, Jaume
  • Segura, Miguel F.|||0000-0003-0916-3618
  • de Torres, Inés|||0000-0002-5495-9140
  • Planas, Jacques|||0000-0002-0222-584X
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Gomis, Roger R..|||0000-0001-6473-2858
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Rodríguez-Barrueco, Ruth|||0000-0003-4925-8865
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
Prostate cancer (PCa) is the most prevalent cancer in males worldwide, and it was the fifth leading cause of cancer mortality in this group in 2020. Near 70% of advanced-stage PCa patients will undergo bone metastasis, suffering pathological complications that severely affect patients' quality of life and probably progress in most cases to lethal PCa. Our main objective was to unveil novel molecules associated with choosing the bone as a metastatic niche. For this purpose, we generated and characterized a cell line with increased tropism to bone. Its molecular analysis has led us to identify factors with a potential role in bone metastasis that could also be used as biomarkers of disease progression. These data help us to understand the mechanisms that increase bone metastasis penetrance of PCa cells and could provide new therapeutic tools in the future for patients with worse prognoses. About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b's role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas, Marc|||0000-0002-2249-8554
  • Masiá, Nuria|||0000-0002-8352-2327
  • Suárez, Leticia|||0000-0002-3864-4616
  • Olivan, Mireia|||0000-0002-8464-0827
  • Soriano, Aroa|||0000-0001-9659-1471
  • Majem Cavaller, Blanca|||0000-0003-3613-0432
  • Devis-Jauregui, Laura|||0000-0003-3736-3983
  • Burgos-Panadero, Rebeca
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Rodriguez-Sodupe, Pau
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Toledano, Ignasi|||0000-0003-0880-8904
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Navarro, Alexandra
  • Llobet Navas, David|||0000-0003-1443-7003
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Roma, Josep|||0000-0001-7692-6123
  • Noguera, Rosa
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Krauss, Rolf
  • Gallego, Soledad|||0000-0002-4712-9624
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Segura, Miguel F.|||0000-0003-0916-3618
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

  • Olivan Riera, Mireia
  • Garcia Lopez, Marta
  • Suarez Cabrera, Leticia
  • Guiu, Marc
  • Gros, Laura
  • Mendez Fernández, Olga
  • Segura Ginard, Miguel
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Morote Robles, Joan
  • De la Cruz Montserrat, Fco. Xavier
  • Santamaria Margalef, Anna
Bone metastasis; MiRNAs; Prostate cancer, Metàstasi òssia; MiRNAs; Càncer de pròstata, Metástasis ósea; MiRNAs; Cáncer de próstata, About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients’ quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells’ migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b’s role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa., The study was supported by grants CPII18/00027 and PI18/01017 to A.S.; PI17/02248 to J.M.; grants PI09/00496, PI13/00173 and postdoctoral fellowship CD12/00475 of Instituto de Salud Carlos III (ISCIII), pre-doctoral fellowship of Vall d’Hebron Research Institute (VHIR), postdoctoral fellowship PERIS of Departament de Salut Govern de Catalunya to M.O.; BBVA and PID2019-104948RB-100 to M.G. (Marc Guiu) and R.R.G.; RD12/0036/0035 of Red Temática de investigación cooperativa en cancer (RTICC), and 2014SGR1330 from “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya”.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas Jimenez, Marc
  • Masia Fandos, Nuria
  • Suarez Cabrera, Leticia
  • Olivan Riera, Mireia
  • Soriano Fernández, Aroa
  • Majem Cavaller, Blanca
  • Jimenez Jimenez, Carlos Gonzalo
  • Boloix Amenós, Ariadna
  • Toledano Martin, Ignasi
  • Navarro Jimenez, Alexandra
  • Sánchez de Toledo Codina, Josep
  • Roma Castanyer, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Santamaria Margalef, Anna
  • Guillén Burrieza, Gabriela
Inhibidor de KIF11; Terapias dirigidas; Metástasis, Inhibidor de KIF11; Teràpies dirigides; Metàstasi, KIF11 inhibitor; Targeted therapies; Metastasis, In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies., The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/01320 to Alberto Villanueva); Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099 to Marc Masanas). This work was also supported by the Asociación NEN (Nico contra el cancer infantil 2017–PVR00157).